Top Anti Cancer Imported Medicine Drugs in India - Pharama Five
Help Desk :+916374297988

Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.

Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org

Best Lumoxiti (Moxetumomab) Medicine in India

Buy Lumoxiti (Moxetumomab) Medicine in India

Lumoxiti (Moxetumomab)

Medicine name : Lumoxiti

Generic name : Moxetumomab

Manufactured By : Innate

Indications : Relapsed or refractory Hairy cell leukemia

Medicine Description : Lumoxiti is an anti-CD22 immunotoxin for relapsed or refractory hairy cell leukemia (HCL). It binds to cancer cells, delivering a toxin that induces cell death. Given via IV infusion, it provides targeted therapy. Side effects include capillary leak syndrome, kidney damage, and low blood counts. Fluid balance and kidney function monitoring are critical.

Product Introduction

Lumoxiti (Moxetumomab Pasudotox) is a targeted anticancer medicine used to treat adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two previous systemic treatments, including a purine nucleoside analog. It is an immunotoxin that targets CD22, a protein found on leukemia cells, helping to destroy abnormal cells.

Lumoxiti is administered by a healthcare professional through an intravenous infusion, usually on specific days of a treatment cycle. The treatment schedule and duration are determined by your doctor based on your condition and response to treatment. Patients are generally advised to drink adequate fluids before and after infusions, and medical monitoring is required during treatment.

Common side effects of Lumoxiti may include infusion-related reactions, swelling, nausea, fatigue, headache, fever, constipation, and changes in kidney function. It can also cause serious conditions such as capillary leak syndrome and hemolytic uremic syndrome (HUS). Inform your doctor immediately if you experience sudden weight gain, swelling, shortness of breath, dizziness, decreased urination, unusual bruising, or severe fatigue. Regular blood tests and kidney-function monitoring may be required during treatment.

Uses Of Lumoxiti (Moxetumomab)

Treatment of Relapsed or Refractory Hairy Cell Leukemia

Benefits Of Lumoxiti

Lumoxiti (Moxetumomab Pasudotox) is used to treat adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two previous systemic treatments, including a purine nucleoside analog. It targets CD22, a protein found on hairy cell leukemia cells, and delivers a toxin directly to these abnormal cells, helping to destroy them. This can reduce the number of leukemia cells and help control the progression of the disease.

Side Effects Of Lumoxiti (Moxetumomab)

Some side effects of Lumoxiti (Moxetumomab Pasudotox) may improve as your body adjusts to the medicine. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Lumoxiti (Moxetumomab)

  • Infusion-related reactions
  • Swelling
  • Nausea
  • Fatigue
  • Headache
  • Fever
  • Constipation
  • Low blood cell counts
  • Changes in kidney function
  • Abnormal liver function tests
How To Use Lumoxiti

Lumoxiti (Moxetumomab Pasudotox) is administered by a healthcare professional through an intravenous infusion. It is usually given on specific days of a treatment cycle, with the exact dose and schedule determined by your doctor. Patients are generally advised to maintain adequate fluid intake before and after treatment to help reduce the risk of kidney problems. Regular blood tests and medical monitoring may be required during treatment.

How Lumoxiti (Moxetumomab) Works

Lumoxiti is a targeted immunotoxin that binds to CD22, a protein found on hairy cell leukemia cells. After binding to these cells, it delivers a toxin inside the cancer cells, which interferes with protein production and causes the abnormal cells to die. This helps reduce leukemia cells and may help control relapsed or refractory hairy cell leukemia (HCL).

Safety Advice

AlcoholCONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment with Lumoxiti (Moxetumomab Pasudotox).

PregnancyCONSULT YOUR DOCTOR

Lumoxiti may harm an unborn baby. Inform your doctor if you are pregnant or planning to become pregnant. Use effective contraception as advised by your doctor.

BreastfeedingCONSULT YOUR DOCTOR

Do not breastfeed during treatment with Lumoxiti. Consult your doctor for guidance.

DrivingCONSULT YOUR DOCTOR

Lumoxiti may cause fatigue, dizziness, or infusion-related reactions that can affect your ability to drive. Avoid driving if these symptoms occur.

KidneyCAUTION

Inform your doctor if you have kidney problems. Adequate hydration and regular kidney-function monitoring may be recommended during treatment.

LiverCAUTION

Tell your doctor if you have liver problems. Your doctor may monitor liver function during treatment.

Quick Tips
  • Attend all scheduled Lumoxiti (Moxetumomab Pasudotox) infusions and follow your doctor's treatment schedule carefully.
  • Drink plenty of fluids before and after treatment as advised by your doctor to help protect your kidneys.
  • Attend regular blood tests to monitor kidney function, blood cell counts, liver function, and other health parameters.
  • Contact your doctor immediately if you experience sudden weight gain, swelling, shortness of breath, dizziness, decreased urination, or unusual bruising.
  • Inform your doctor about all medicines, vitamins, herbal products, and dietary supplements you are taking to help prevent possible drug interactions.
  • Read More About - Lumoxiti (Moxetumomab) from Pharma Five.
Faq

General Question

Lumoxiti (Moxetumomab pasudotox-tdfk) is a prescription medicine used to treat adults with relapsed or refractory hairy cell leukemia (HCL) after at least two prior systemic therapies, including a purine nucleoside analog.

Lumoxiti is a CD22-directed cytotoxin. It binds to CD22, a protein found on certain leukemia cells, and delivers a toxin that kills the cancer cells.

Lumoxiti is for adult patients with hairy cell leukemia who have already tried at least two treatments without successful results.

Lumoxiti is given as an intravenous (IV) infusion by a healthcare provider, typically on days 1, 3, and 5 of a 28-day cycle, for up to 6 cycles depending on response and tolerance.

Common side effects include swelling, nausea, fatigue, headache, fever, and infusion-related reactions.

Yes, Lumoxiti can cause serious side effects such as capillary leak syndrome (CLS), hemolytic uremic syndrome (HUS), kidney problems, and low blood counts. Report symptoms like sudden weight gain, low urine output, or swelling immediately.

Treatment usually continues for up to 6 cycles unless side effects become severe or the disease progresses. Your doctor will determine the duration based on your condition.

It’s best to avoid alcohol during treatment as it may stress your kidneys and liver, which are already monitored closely during Lumoxiti therapy.

No, Lumoxiti may harm an unborn baby. Effective contraception is recommended during treatment and for some time afterward.

Yes, Lumoxiti may interact with other medicines. Inform your healthcare provider about all the drugs and supplements you are taking.

Lumoxiti is administered by healthcare professionals. If you miss an appointment, contact your clinic immediately to reschedule the dose.

Lumoxiti is given by IV infusion, so food doesn’t directly impact its administration, but maintaining hydration is important during treatment.

Stay hydrated, watch for symptoms of serious side effects like fluid retention or kidney issues, and attend all scheduled blood and urine tests.

Lumoxiti is stored and prepared by healthcare providers in a medical facility; patients do not need to store it at home.

Lumoxiti is administered at specialized treatment centers or hospitals. Your oncologist will direct you to the appropriate facility for treatment. Pharma Five assists in its procurement.